Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Bland–Altman plots of in vitro functional residual capacity.

Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Bland–Altman plot of slopes of measurement 1 versus 2

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

Kaplan–Meier curves of long-term survival in young (

Health-related quality of life measured by the RAND 36-Item Health Survey according to modified Medical Research Council (mMRC) dyspnoea scale groups.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

The variability of probability of that the length of stay is longer than the median by country. The variability of probability of that the length of stay.

Axial CT scans of the chest. a) Before treatment

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Concentration of inflammatory cytokines in epithelial lining fluid (ELF) were plotted for the normal control, smoker normal forced oscillation technique.

Average mean arterial pressure (Pa) during lung volume recruitment (LVR) in (a) the respiratory muscle weakness (RMW) group and (b) the control group.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

a) Mortality per time point (p<0

Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

The regression lines between the asynchrony index (AI) and the double true index (DTI) shown for overall data, and for mask and helmet separately. The.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Serum concentrations of procollagen type I C-peptide (PICP), Fas ligand, osteopontin (OPN) and matrix metalloproteinase (MMP)-7 in healthy controls (HCs)

Relationship between bronchodilator response of physiological parameters and concentration of interleukin (IL)-8 in epithelial lining fluid (ELF). Relationship.

SGRQ total scores by (A) FVC % predicted at baseline and (B) use of supplemental oxygen at baseline. SGRQ total scores by (A) FVC % predicted at baseline.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

A–d) Bland–Altman plots of absolute differences between tremoFlo at 5 and 7 Hz versus the mean of the two measurements in resistance R and reactance X.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Plots showing baseline correlation between the modified Medical Research Council (mMRC) dyspnoea scale, Baseline Dyspnoea Index (BDI), COPD Assessment.

Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation in year 1 and year 2 (full cohort, year 1 or year 2). a)

Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Comparison of exhaled H2O2 values in chronic obstructive pulmonary disease (COPD) patients (n=12) and control group (n=9). a) Raw ambient air concentrations.

Presentation transcript:

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration at baseline. Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration at baseline. The regression line (grey line) and 95% confidence interval (grey area) are represented. FVC: forced vital capacity; MMP: matrix metalloproteinase. Yasmina Bauer et al. ERJ Open Res 2017;3:00074-2016 ©2017 by European Respiratory Society